---

$3.67

-0.0700 ( -1.87% ) 56.8K

Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.

Type: All Buy Sale Start date: End date: Filter Reset

Date	Type	Amount Purchased	Purchaser
2024-06-28	Sale	-16000.00	SMITH IAN F
2024-06-28	Sale	-16000.00	Mendelsohn Michael
2024-06-28	Sale	-16000.00	GILL SIMBA
2024-06-28	Sale	-16000.00	Biller Scott
2024-06-28	Sale	-16000.00	Lynch Thomas J. Jr.
2024-06-28	Sale	-16000.00	Cole Douglas G.
2024-06-28	Sale	-16000.00	Koppel Adam
2024-06-28	Sale	-16000.00	PARSHALL B LYNNE
2024-06-24	Sale	0.00	Cavalie Fanny
2024-05-24	Buy	1814914.00	Flagship Pioneering Inc.